Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 29, 2021 07:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics Announces Late-Breaking Presentation at 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

STAMFORD, Conn., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
September 24, 2021 07:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference

STAMFORD, Conn., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
August 23, 2021 15:41 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis Promotional launch of KORSUVA™ injection in...
August 09, 2021 16:01 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics Reports Second Quarter 2021 Financial Results

– New Drug Application (NDA) Filing for KORSUVA™ Injection in CKD-aP under Priority Review by U.S. Food and Drug Administration (FDA); PDUFA Target Action Date August 23, 2021 – – Conference call...
August 02, 2021 16:01 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics to Announce Second Quarter 2021 Financial Results on August 9, 2021

STAMFORD, Conn., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
May 25, 2021 07:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics to Present at the Jefferies Healthcare Conference

STAMFORD, Conn., May 25, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
May 10, 2021 16:01 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics Reports First Quarter 2021 Financial Results

– U.S. Food and Drug Administration (FDA) Accepts New Drug Application (NDA) Filing and Grants Priority Review for KORSUVA™ Injection in CKD-aP – – Conference call today at 4:30 p.m. ET – STAMFORD,...
May 06, 2021 16:01 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

STAMFORD, Conn., May 06, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
May 03, 2021 16:01 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021

STAMFORD, Conn., May 03, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
April 29, 2021 07:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

– Study did not meet Primary Endpoint of worst-itch NRS change from baseline at week 12 or Secondary Endpoint of 4-point responder analysis in the ITT patient population – Study...